Edysta
Generic Name
Edoxaban
Manufacturer
Beacon Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| edysta 25 mg tablet | ৳ 10.00 | ৳ 100.00 |
Description
Overview of the medicine
Edoxaban is an oral anticoagulant that directly inhibits Factor Xa, an enzyme central to the coagulation cascade. It is used to prevent and treat various thromboembolic conditions, such as stroke in atrial fibrillation and deep vein thrombosis/pulmonary embolism.
Uses & Indications
Dosage
Adults
For NVAF: 60 mg once daily. For DVT/PE: 60 mg once daily after 5-10 days of initial parenteral anticoagulant therapy. Dosage adjustment to 30 mg once daily for certain conditions (e.g., CrCl 15-50 mL/min, low body weight, concomitant P-gp inhibitors).
Elderly
No specific dose adjustment based solely on age, but consider renal function and other risk factors for bleeding.
Renal_impairment
For patients with CrCl 15-50 mL/min, reduce dose to 30 mg once daily. Not recommended for CrCl > 95 mL/min (for NVAF) or CrCl < 15 mL/min (for all indications).
How to Take
Oral administration, with or without food. Swallow the tablet whole with water. May be administered via a nasogastric (NG) tube or gastrostomy tube after crushing and mixing with water.
Mechanism of Action
Edoxaban is a highly selective, direct, and reversible inhibitor of Factor Xa. By inhibiting Factor Xa, it prevents prothrombinase complex formation, thus inhibiting thrombin generation and thrombus formation.
Pharmacokinetics
Onset
Within 1-2 hours
Excretion
Mainly via renal excretion (approximately 50%), with remaining excretion via hepatobiliary route.
Half life
Approximately 10-14 hours
Absorption
Rapidly absorbed, peak plasma concentration reached within 1-2 hours. Bioavailability is approximately 62%.
Metabolism
Minimally metabolized; primarily excreted unchanged.
Side Effects
Contraindications
- •Active pathological bleeding.
- •Hypersensitivity to Edoxaban or any component of the formulation.
- •Severe uncontrolled hypertension.
- •Hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
Drug Interactions
NSAIDs/SSRIs
Increased risk of bleeding.
P-gp inhibitors (e.g., Cyclosporine, Dronedarone, Erythromycin, Ketoconazole)
May increase Edoxaban exposure, requiring dose reduction to 30 mg for NVAF.
Other anticoagulants/antiplatelet agents (e.g., Aspirin, Clopidogrel, Warfarin)
Increased risk of bleeding.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach and sight of children.
Overdose
There is no specific antidote for edoxaban. Activated charcoal may be used to reduce absorption. Management includes supportive care and symptomatic treatment. Consider factor Xa reversal agents (e.g., Andexanet alfa) if available and clinically indicated for severe, uncontrolled bleeding.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Avoid use during breastfeeding as it is unknown if edoxaban is excreted in human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from the date of manufacture, specific details on packaging.
Availability
Pharmacies, hospitals
Approval Status
FDA Approved
Patent Status
Patent protected in some regions, generic versions available in others
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
